CNS Pharmaceuticals Inc (NASDAQ: CNSP) today announced that the U.S. Food and Drug Administration (FDA) had approved Fast Track Description for its untried lead medication, Berubicin, for the cure of patients with recurring glioblastoma multiforme (GBM). Drug to be used for the Cure of Recurring Glioblastoma Multiforme The company has […]